About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target ...

Research teams from Augusta University, Massachusetts General Hospital and The Ohio State University will lead a $15 million project dedicated to studying the various ways that risk factors for ...

Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. The disease ...

Palvella noted that QTORIN rapamycin may become the first FDA-approved treatment and standard of care for microcystic LMs ... therapy for this debilitating disease." QTORIN rapamycin has received ...